A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

被引：13
|
作者：
Casal Rubio, Joaquin [1 ]
Vazquez, S. [2 ]
Vazquez, F. [3 ]
Amenedo, M. [4 ]
Firvida, J. L. [5 ]
Mel, J. R. [2 ]
Huidobro, G. [1 ]
Alvarez, E. [2 ]
Lazaro, M. [1 ]
Alonso, G. [6 ]
Fernandez, I. [7 ]
机构：
[1] Hosp Meixoeiro, Dept Med Oncol, Vigo 36200, Pontevedra, Spain
[2] Complejo Hosp Xeral Calde, Lugo, Spain
[3] Hosp Arquitecto Marcide, Ferrol, Spain
[4] Ctr Oncol Galicia, La Coruna, Spain
[5] Complejo Hosp, Orense, Spain
[6] Hosp Juan Canalejo, La Coruna, Spain
[7] Hosp Montecelo, Pontevedra, Spain
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2009年 / 64卷 / 02期
关键词：
Chemotherapy; Cisplatin; Docetaxel; Gemcitabine; Non-small cell lung cancer; Phase II trial; PLATINUM-BASED CHEMOTHERAPY; CANCER; COMBINATION; METAANALYSIS; VINORELBINE; ERLOTINIB; EFFICACY; REGIMEN;
D O I：
10.1007/s00280-008-0884-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
To test efficacy and tolerability of non-platinum regimens for advanced non-small-cell lung cancer (NSCLC). Chemonaive patients with measurable stage IIIB/IV NSCLC treated with gemcitabine and cisplatin (GC), or gemcitabine and docetaxel (GD), maximumsix cycles in a phase IIB trial. A total of 108 patients were randomized. Response rates (GC vs. GD, respectively): complete 3.6/2.0%, Partial 30.9/38.0%. Median Overall Survival (OS): 8.9 months in both groups (P = 0.53); and median time to progression (TTP): 6.2/5.5 months respectively (P = 0.61). Toxicities included (GC vs. GD, respectively): grade 3-4 neutropenia 49.1/41.2%; grade 3 thrombocytopenia 30.9/3.9%; grade 3 anemia 14.5/3.9%. Non-haematological toxicity was similar, except for nausea and vomiting, (16.3/2%); renal toxicity (3.7/0%) and hepatic toxicity (5.6/12.7%). With a higher overall response rate and lower toxicity, GD is a good first treatment option for advanced NSCLC.
引用
收藏
页码：379 / 384
页数：6
相关论文
共 50 条
  • [21] Gemcitabine-docetaxel versus cisplatin.-vinorelbine in advanced or metastatic non-small-cell lung cancer:: a phase III study addressing the case for cisplatin
    Pujol, JL
    Breton, JL
    Gervais, R
    Rebattu, P
    Depierre, A
    Morére, JF
    Milleron, B
    Debieuvre, D
    Castéra, D
    Souquet, PJ
    Moro-Sibilot, D
    Lemarié, E
    Kessler, R
    Janicot, H
    Braun, D
    Spaeth, D
    Quantin, X
    Clary, C
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (04) : 602 - 610
  • [22] Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III randomized trial
    Georgoulias, V
    Ardavanis, A
    Tsiafaki, X
    Agelidou, A
    Mixalopoulou, P
    Anagnostopoulou, O
    Ziotopoulos, P
    Toubis, M
    Syrigos, K
    Samaras, N
    Polyzos, A
    Christou, A
    Kakolyris, S
    Kouroussis, C
    Androulakis, N
    Samonis, G
    Chatzidaki, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2937 - 2945
  • [23] Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC)
    Antón, A
    Díaz-Fernández, N
    Larriba, JG
    Vadell, C
    Masutti, B
    Montalar, J
    Barneto, I
    Artal, A
    Rosell, R
    [J]. LUNG CANCER, 1998, 22 (02) : 139 - 148
  • [24] Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer:: a phase II trial
    Laack, E
    Mende, T
    Dürk, H
    Kneba, M
    Dickgreber, N
    Welte, T
    Müller, T
    Scholtze, J
    Graeven, U
    Jasiewicz, Y
    Edler, L
    Hossfeld, DK
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (05) : 654 - 660
  • [25] A phase II trial of the combination of gemcitabine, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer
    Vadell-Nadal, C
    Nogué-Aliguer, M
    Fabregat-Mayol, X
    Saigí-Grau, E
    Gallén-Castillo, M
    [J]. LUNG CANCER, 2000, 28 (02) : 109 - 115
  • [26] A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer
    Pallis, AG
    Agelidou, A
    Papakotoulas, P
    Tsaroucha, A
    Agelidou, M
    Agelaki, S
    Androulakis, N
    Vamvakas, L
    Gerogianni, A
    Kotsakis, A
    Kentepozidis, N
    Georgoulias, V
    [J]. LUNG CANCER, 2006, 52 (02) : 165 - 171
  • [27] A phase II study of gemcitabine with cisplatin in patients with non-small cell lung cancer
    Abratt, RP
    Bezwoda, WR
    Goedhals, L
    Hacking, DJ
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1086 - 1086
  • [28] Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer
    Johan Vansteenkiste
    Jean-Luc Canon
    Henrik Riska
    Robert Pirker
    Patrick Peterson
    William John
    Pekka Mali
    Michael Lahn
    [J]. Investigational New Drugs, 2005, 23 : 263 - 269
  • [29] Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma
    Abratt, RP
    Hacking, DJ
    Goedhals, L
    Bezwoda, WR
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (03) : 818 - 823
  • [30] Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer
    Vansteenkiste, J
    Canon, JL
    Riska, H
    Pirker, R
    Peterson, P
    John, W
    Mali, P
    Lahn, M
    [J]. INVESTIGATIONAL NEW DRUGS, 2005, 23 (03) : 263 - 269
12345